11-Jan-2021
European Commission grants 3 NNZ-2591 Orphan designations European Commission grants 3 NNZ-2591 Orphan designations

7-Dec-2020
Notification of investor briefing webinar Notification of investor briefing webinar

7-Dec-2020
Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591 Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591

19-Nov-2020
Approval received for final stage of NNZ-2591 clinical trial Approval received for final stage of NNZ-2591 clinical trial

29-Oct-2020
Quarterly report and cash flow statement for Q3 2020 Quarterly report and cash flow statement for Q3 2020

29-Sep-2020
Neuren requests Orphan designations for NNZ-2591 in Europe Neuren requests Orphan designations for NNZ-2591 in Europe

22-Sep-2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials Neuren initiates manufacture of NNZ-2591 for Phase 2 trials

26-Aug-2020
Half-year Shareholder Update Half-year Shareholder Update

26-Aug-2020
Half Yearly Report and Accounts Half Yearly Report and Accounts

18-Aug-2020
Corporate presentation, 18 August 2020 Corporate presentation, 18 August 2020